

Markers for emphysema versus airways disease in chronic obstructive pulmonary disease (COPD)

Submission date 21/05/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☒ Protocol
Registration date 21/05/2010	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 27/09/2018	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Dave Singh

Contact details
Medicines Evaluation Unit Ltd
The Langley Building
Southmoor Road
Wythenshawe
Manchester
United Kingdom
M23 9QZ
-
dsingh@meu.org.uk

Additional identifiers

Protocol serial number
5323

Study information

Scientific Title

Markers for emphysema versus airways disease in chronic obstructive pulmonary disease (COPD)

Acronym

Markers for Emphysema versus Airways disease in COPD

Study objectives

Our hypothesis is that the mechanisms leading to emphysema and airway disease are distinct with respect to the type of inflammatory response in terms of genetic predisposition. The differential pathogenesis for emphysema and inflammatory airway disease entails that the two forms of COPD are linked to different markers at the DNA, RNA and protein level.

The project aims at identifying these markers. The markers will be elements involved in a differential pathogenesis for the different disease processes in COPD. They can be used for diagnostic approaches and therapeutic targets.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved (ref: 08/H0402/19)

Study design

Multicentre non-randomised observational prevention and cohort study

Primary study design

Observational

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Topic: Respiratory; Subtopic: Respiratory (all Subtopics); Disease: Respiratory

Interventions

1. Blood sample
2. Bronchoscopy
3. Computed tomography (CT) Scan
4. Lung samples
5. Sputum collection

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

To use CT scanning to identify patients with COPD with predominant airway wall changes

Key secondary outcome(s))

1. Development of new diagnostic tools and to new therapies for COPD
2. Understanding differences in pattern of inflammation and genetic predisposition

Completion date

31/03/2011

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex**Key exclusion criteria**

Not provided at time of registration

Date of first enrolment

01/04/2008

Date of final enrolment

31/03/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Medicines Evaluation Unit Ltd

Manchester

United Kingdom

M23 9QZ

Sponsor information

Organisation

University Hospitals of Leicester NHS Trust (UK)

ROR

<https://ror.org/02fha3693>

Funder(s)**Funder type**

Government

Funder Name

European Commission (Belgium)

Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2016		Yes	No
Protocol article	protocol	01/10/2012		Yes	No